Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers.
Drilon A, Schoenfeld AJ, Arbour KC, Litvak A, Ni A, Montecalvo J, Yu HA, Panora E, Ahn L, Kennedy M, Haughney-Siller A, Miller V, Ginsberg M, Ladanyi M, Arcila M, Rekhtman N, Kris MG, Riely GJ.
Drilon A, et al. Among authors: kris mg.
Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2):a003665. doi: 10.1101/mcs.a003665. Print 2019 Apr.
Cold Spring Harb Mol Case Stud. 2019.
PMID: 30936194
Free PMC article.
Clinical Trial.